title: Emerging therapies for fibromyalgia.
abstract: BACKGROUND
  Fibromyalgia syndrome (FMS) is a disorder characterized by widespread pain, tenderness, and fatigue. High prevalence marks the syndrome which is considered to reflect altered central pain processing. Fibromyalgia syndrome runs a chronic, non-progressive course, extracting high price owing to impaired quality of life, restricted vocational capacity, and increased health care utilization.
  
  
  OBJECTIVE
  To review current and emerging trends in the treatment of FMS.
  
  
  METHODS
  A rigorous search of published literature, abstract presentations, and industry provided data was performed.
  
  
  CONCLUSIONS
  The recent FDA approval of pregabalin as a first specific medication for FMS may herald a new era for the development of medications with higher specificity and efficacy for this hitherto frustrating condition.
authors.affiliation: Tel Aviv Sourasky Medical Center, Rheumatology Institute, Tel Aviv, Israel.
authors.forename: Jacob N
authors.initials: JN
authors.lastname: Ablin
authors.forename: Dan
authors.initials: D
authors.lastname: Buskila
mesh_terms: D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use*; D005356:Fibromyalgia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D010146:Pain / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D010147:Pain Measurement / Q000187:drug effects
chemical_list: D000700:Analgesics; D000927:Anticonvulsants; D000928:Antidepressive Agents; D015507:Drugs, Investigational